The American Journal of Pharmacy Benefits
May/June 2014
Drug Trends
Paige Berger
As we shift the healthcare paradigm, new ways to lower costs and improve adherence are worth another look.
From the Editor
Jan E. Berger, MD, MJā€”Editor-in-Chief
There are 10 steps that need to be taken to help payers more adequately address the problem of inappropriate prescribing of pain medications.
Original Research
Jan Berger, MD, MJ; Louis L. Brunetti, MD; Robert DaSilva, RPh; Shareh O. Ghani, MD; Kevin Hirsch, MD; Mumtaz Ibrahim, MD; Michael Kobernick, MD, MS, FAAEM, FAAFP; Robin J. Richardson, RPh; Scott Schnuckle; Justin Weiss, PharmD; and Richard Bankowitz, MD, MBA, FACP
Executive-level pharmacy leaders in US managed care organizations identify how healthcare reform is driving changes in pharmacy benefit management.
Qian Cai, MS, MSPH; Chureen Carter, PharmD, MS; Azza AbuDagga, PhD, MHA; Brad Schenkel, MS; Megan Jones, PharmD, MPA; and Hiangkiat Tan, BPharm, MS
This study is an evaluation of the dosing patterns of ustekinumab among patients with psoriasis in a real-world setting.
Patient Advocacy
Myrl Weinberg, FASAE, CAE
Congress has passed a law designed to get advanced diagnostic tests to patients more quickly and to promote personalized care for patients.
Specialty Healthcare Benefits Council
Stephen Altenburger, PharmD; and Maureen Miller, MPH, BSN
The 2014 CMS Coverage Determination and Appeals audit will challenge plans providing Medicare Part D services, and could lead to a cascading impact much larger than audit failure alone.
Web Exclusives
Allison M. Bell, PharmD, MSc, BCPS; Mitra Corral, MS, MPH; John R. Penrod, PhD; Ying Zhang, MD, MSPH; Christopher R. Frei, PharmD, MSc, BCPS; Laurajo Ryan, PharmD, MSc, BCPS, CDE; Mark E. Salvati, PhD; and Jim M. Koeller, MS
We characterized the direct cost of stage 4 non-small cell lung cancer from 2000 to 2009, with a focus on drug treatments.
Ozgur Tunceli, PhD; David M. Kern, MS; Setareh A. Williams, PhD; Ned Pethick, MBA; Lisa Suchower, MA; and Sulabha Ramachandran, PhD
This study compares the initiation of asthma therapies in a real-world population.
Anna Kaltenboeck, MA; Jasmina Ivanova, MS; Howard Birnbaum, PhD; Yana Yushkina, BA; Frances Schwiep, BA; Kelly Bell, PharmD; and Nina Thomas, MPH
Controlling for baseline characteristics, saxagliptin patients had lower medical costs compared with sulfonylurea patients, and lower medical and total costs than sitagliptin patients.
Kristine Ogden, BS; Shuchita Kaila, PhD; and Nancy Neil, PhD
This model analysis explores the budget impact of prescribing single-pill fixed dose versus loose-dose combination triple therapies for hypertension.